CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

CervoMed Inc. (NASDAQ:CRVO) earns a place on our top 10 stocks under $5 that could triple.

CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

On March 17, 2026, CervoMed Inc. (NASDAQ:CRVO) announced results for the fourth quarter and full year 2025. The company highlighted advancements in its neflamapimod program for dementia with Lewy bodies (DLB).

CervoMed Inc. (NASDAQ:CRVO) further reported favorable Phase 2b RewinD-LB data at CTAD 2025 while achieving an agreement with the FDA and international authorities on the design of a Phase 3 trial. This trial is expected to commence in the latter part of 2026. With the start of the EXPERTS-ALS investigation and topline findings from Phase 2a trials in ischemic stroke recovery and primary progressive aphasia, the upcoming calendar remains catalyst-heavy.

In terms of finances, CervoMed Inc. (NASDAQ:CRVO) reported $20.9 million in cash as of December 31, 2025, indicating a runway of roughly six months, with R&D expenses of $21.8 million and a net loss of $27.0 million for the year.

A day later, Boobalan Pachaiyappan of Roth Capital reduced the price target on CervoMed Inc. (NASDAQ:CRVO) from $19 to $11 while keeping a “Buy” rating. The analyst noted that results were largely in line with expectations, but the company may need to raise capital on less favorable terms.

CervoMed Inc. (NASDAQ:CRVO) is a clinical-stage biotechnology firm specializing in CNS-targeted therapeutics, namely, neflamapimod, aimed at neurodegenerative conditions such as dementia with Lewy bodies, stroke rehabilitation, and several other cerebral disorders.

While we acknowledge the risk and potential of CRVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRVO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.